• Study design
  • primary endpoints
  • secondary endpoint

The IOP-lowering effect of VYZULTA® was evaluated
in two Phase 3 studies (APOLLO & LUNAR)

APOLLO & LUNAR study designs1,3,4

  • Randomized, multicenter, double-masked, non-inferiority, pivotal clinical trials performed in the United States and Europe
  • Study populations included adult males and non-pregnant adult females with open-angle glaucoma or ocular hypertension